Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
Gilead Sciences is putting a hold on the Japan development of its anti-HIV therapy Sunlenca (lenacapavir) for pre-exposure prophylaxis (PrEP) due to the country’s reimbursement challenges for preventive medicines. This might give rise to a new drug loss if the…
To read the full story
Related Article
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Gilead Seeks Lawmakers’ Backing for Public Subsidies in PrEP
May 21, 2025
- MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
- Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
September 14, 2023
BUSINESS
- Healios Countersues AND Medical over Unpaid Milestone
June 10, 2026
- Moderna Japan Looks Beyond COVID for Next Growth Pillars
June 9, 2026
- Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
- CSL Behring Japan President Yoshida to Step Down
June 8, 2026
- Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…